TY - JOUR
T1 - Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents
AU - Bone-D study group
AU - Sudjaritruk, Tavitiya
AU - Bunupuradah, Torsak
AU - Aurpibul, Linda
AU - Kosalaraksa, Pope
AU - Kurniati, Nia
AU - Sophonphan, Jiratchaya
AU - Ananworanich, Jintanat
AU - Puthanakit, Thanyawee
N1 - Funding Information:
Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand: C Sopharuk and P Tharnprisan. The study was funded by TREAT Asia/amfAR, The Foundation for AIDS Research, through a grant from ViiV Healthcare. The views expressed are those of the authors and should not be construed to represent the positions of the US Army or the Department of Defense or any of the institutions mentioned above. TS is funded in part by the National Research University Project under Thailand’s Office of the Higher Education Commission. TP is funded in part by the Thailand Research Fund Institutional Grant (IRG5780015). Data were presented in part at the 7th International Workshop on HIV Pediatrics, 17–18 July 2015, Vancouver, Canada.
Funding Information:
TS is funded in part by the National Research University Project under Thailand’s Office of the Higher Education Commission. TP is funded in part by the Thailand Research Fund Institutional Grant (IRG5780015). Data were presented in part at the 7th International Workshop on HIV Pediatrics, 17–18 July 2015, Vancouver, Canada.
Publisher Copyright:
© 2017 International Medical Press.
PY - 2017
Y1 - 2017
N2 - Background: This study aimed to determine the effect of tenofovir disoproxil fumarate (TDF) on bone metabolism and bone mass in HIV-infected adolescents. Methods: This was a sub-study of a cross-sectional multicentre bone health trial that enrolled perinatally HIV-infected Thai and Indonesian adolescents (10–18 years) with viral suppression on antiretroviral therapy. Participants were classified into two groups as TDF users and non-users. Bone metabolism-related markers (25-hydroxyvitamin D [25-OHD], intact parathyroid hormone [iPTH], bone turnover biomarkers), and lumbar spine dual-energy X-ray absorptiometry were assessed. Bone mineral density (BMD)/bone mineral apparent density (BMAD) Z-scores were calculated. Results: Of 394 adolescents, 136 (34.5%) and 258 (65.5%) were TDF users and non-users, respectively. Among TDF users, median age (IQR) was 16.1 (14.7–17.4) years and TDF treatment duration (IQR) was 2.3 (1.4–3.1) years. Among TDF non-users, median age (IQR) was 14.3 (12.6–16.4) years. BMD and BMAD Z-scores comparing TDF users with non-users were -0.8 and -0.6 (P=0.27), and -0.3 and -0.2 (P=0.58), respectively. The association between TDF use and iPTH elevation was intensified in adolescents with suboptimal vitamin D levels (25-OHD <30 ng/ml; P=0.001). TDF administration was positively associated with bone resorption marker (P=0.04) and negatively associated with bone formation marker (P=0.04). With data up to 4 years, neither association between TDF use and bone mass loss (BMD: P=0.09; BMAD: P=0.22), nor variation of bone mass Z-scores by TDF treatment duration (BMD: P=0.34; BMAD: P=0.58) was demonstrated. Conclusions: Recent TDF administration was correlated with PTH elevation and bone turnover dysregulation but not with bone mass reduction in our cohort. A study with extended follow-up to ascertain TDF-associated bone mass deterioration is warranted.
AB - Background: This study aimed to determine the effect of tenofovir disoproxil fumarate (TDF) on bone metabolism and bone mass in HIV-infected adolescents. Methods: This was a sub-study of a cross-sectional multicentre bone health trial that enrolled perinatally HIV-infected Thai and Indonesian adolescents (10–18 years) with viral suppression on antiretroviral therapy. Participants were classified into two groups as TDF users and non-users. Bone metabolism-related markers (25-hydroxyvitamin D [25-OHD], intact parathyroid hormone [iPTH], bone turnover biomarkers), and lumbar spine dual-energy X-ray absorptiometry were assessed. Bone mineral density (BMD)/bone mineral apparent density (BMAD) Z-scores were calculated. Results: Of 394 adolescents, 136 (34.5%) and 258 (65.5%) were TDF users and non-users, respectively. Among TDF users, median age (IQR) was 16.1 (14.7–17.4) years and TDF treatment duration (IQR) was 2.3 (1.4–3.1) years. Among TDF non-users, median age (IQR) was 14.3 (12.6–16.4) years. BMD and BMAD Z-scores comparing TDF users with non-users were -0.8 and -0.6 (P=0.27), and -0.3 and -0.2 (P=0.58), respectively. The association between TDF use and iPTH elevation was intensified in adolescents with suboptimal vitamin D levels (25-OHD <30 ng/ml; P=0.001). TDF administration was positively associated with bone resorption marker (P=0.04) and negatively associated with bone formation marker (P=0.04). With data up to 4 years, neither association between TDF use and bone mass loss (BMD: P=0.09; BMAD: P=0.22), nor variation of bone mass Z-scores by TDF treatment duration (BMD: P=0.34; BMAD: P=0.58) was demonstrated. Conclusions: Recent TDF administration was correlated with PTH elevation and bone turnover dysregulation but not with bone mass reduction in our cohort. A study with extended follow-up to ascertain TDF-associated bone mass deterioration is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85037044596&partnerID=8YFLogxK
U2 - 10.3851/IMP3103
DO - 10.3851/IMP3103
M3 - Article
C2 - 27786155
AN - SCOPUS:85037044596
VL - 22
SP - 471
EP - 479
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 6
ER -